Detection of blaNDM-1 in Stenotrophomonas maltophilia isolated from Brazilian soil

Furlan, João Pedro Rueda; Pitondo-Silva, André; Stehling, Eliana Guedes

doi:10.1590/0074-02760170558

Cited by 15 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the first description of blaNDM-1 gene in 2008 in Klebsiella pneumoniae (Yong, et al, 2009), several studies have reported the spread of this gene, with an increasing emphasis on the genus Acinetobacter spp. (Adams, et al, 2020, Chatterjee, et al, 2016, Dortet, et al, 2012, Fernández-Cuenca, et al, 2020, Furlan, et al,2018, Joshi,et al, 2017, Kumari, et al, 2021, Pagano, et al, 2015, Pasteran, et al, 2014, Pillonetto, et al, 2014, Poirel, et al, 2011, Rozales, et al, 2014, Tran, et al, 2017, Woodford, et al, 2006, Zhang, et al, 2013, Zhang, et al, 2014.…”

Section: Discussionmentioning

confidence: 99%

Co-production of blaNDM-1 and blaOXA-23 in multiresistant clinical isolates of Acinetobacter baumannii from Brazil

Lopes

Évora²,

Oliveira³

et al. 2022

RSD

View full text Add to dashboard Cite

Acinetobacter baumannii is a common and dangerous non-fermenting gram-negative bacillus due to its various and increasing resistance mechanisms. Therefore, the objective of the work was to describe four NDM-1 -producing Acinetobacter isolates from Natal, northeastern Brazil. These four isolates were identified as Acinetobacter baumannii by MALDI-TOF. All isolates were characterized by antimicrobial susceptibility testing, with resistance to all β-lactams including carbapenems and positive for the synergy test with Ethylenediaminetetraacetic acid. PCR analysis was also performed for blaNDM-1, blaVIM-1, blaIMP-1, blaOXA-23, blaOXA-24/40, blaOXA-51, blaOXA-58, and blaOXA-143 genes and showed positive for the blaNDM-1 and blaOXA-23 genes in all isolates and this result was confirmed by sequencing. This is the first case of Acinetobacter baumannii strains harboring blaNDM-1 gene isolated from northeastern Brazil. This description emphasizes the need for new prevention and control strategies of the dissemination of NDM-1-producing Acinetobacter, which are associated with a high mortality rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Co-production of blaNDM-1 and blaOXA-23 in multiresistant clinical isolates of Acinetobacter baumannii from Brazil

Lopes

Évora²,

Oliveira³

et al. 2022

RSD

View full text Add to dashboard Cite

show abstract

“…Indeed, sul1, sul2 and dfrA conferring resistance to SXT have been found chromosomally and in plasmids, and associated with Class 1 integrons and insertion sequence common region (ISCR) elements that enhance their mobility [2,54,55]. Likewise, other b-lactamase genes, such as bla CTX-M , bla NDM-1 , and bla IMP-8 have also been reported on plasmids in clinical and environmental Sma strains [35,[56][57][58][59].…”

Section: Acquired Molecular Mechanisms Of Resistancementioning

confidence: 99%

Treatment approaches for severe Stenotrophomonas maltophilia infections

Mojica,

Bonomo,

van Duin

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Stenotrophomonas maltophilia is an emerged opportunistic pathogen. Intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Herein, we provide an update on the most recent literature on treatment options for severe S. maltophilia infections. Recent findings Trimethoprim-sulfamethoxazole (SXT) is recognized as the first-line therapy for S. maltophilia infections. However, its clinical use is based on good in vitro activity and favorable clinical outcomes, rather than on solid minimum inhibitory concentration (MIC) correlations with pharmacokinetic/pharmacodynamics (PK/PD) and/or clinical outcomes. The same is true for other treatment options like levofloxacin (LVX) and minocycline (MIN). Recent PK/PD studies question the current clinical breakpoints for SXT, LVX, and MIN. Based on this, the latest guidance issued by the Infectious Diseases Society of America (IDSA) recommends using these agents only as part of a combination therapy. Alternatively, novel therapeutic options such as cefiderocol (FDC) and ceftazidime-avibactam plus aztreonam (CZA-ATM) are suggested, based on limited but promising clinical data. Summary PK/PD data and controlled clinical studies are needed to optimize current treatment options. Presently, combination therapy of SXT, LVX, MIN, or FDC, or monotherapy with CZA-ATM are recommended therapeutic options for severe-to-moderate S. maltophilia infections.

show abstract

“…L1 is a Zn+ dependent β-lactamases which ensures that S. maltophilia is resistant to cephalosporines, carbapenem, penicillin's, and not monobactam, L2 however is an acid sensitive cephalosporine which confers resistance on S. maltophilia to cephalosporines, monobactam and penicillin 20 , 21 . Other mechanisms that have been reported in Stenotrophomonas species include plasmid borne resistant gene such as bla PER born on IncA/C Plasmid and bla NDM which conferred extended beta-lactam resistance on a strain of S. maltophilia isolated from the soil in Brazil 22 . Resistant mechanisms described above in Stenotrophomonas species might be due to the possession of extra-chromosomal genes acquired from other bacteria.…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial susceptibility pattern of Stenotrophomonas species isolated from Mexico

Elufisan¹,

Luna²,

Oyedara³

et al. 2020

Afr H. Sci.

View full text Add to dashboard Cite

Background: Stenotrophomonas species are multi-resistant bacteria with ability to cause opportunistic infections. Objective: We isolated 45 Stenotrophomonas species from soil, sewage and the clinic with the aim of investigating their susceptibility to commonly used antimicrobial agents. Methodology: The identities of isolates were confirmed with 16S rRNA gene sequence and MALDI-TOF analysis. Anti-mi- crobial resistance, biofilm production and clonal diversity were also evaluated. The minimum inhibitory concentration technique as described by Clinical & Laboratory Standards Institute: CLSI Guidelines (CLSI) was employed for the evaluation of isolate susceptibility to antibiotics. Result: Forty-five Stenotrophomonas species which include 36 environmental strains and 9 clinical strains of S. maltophilia were considered in this study. 32 (88.9 %) environmental strains were identified to be S. maltophilia, 2 (5.6 %) were Stenotrophomonas nitritireducens, and 2 (5.6 %) cluster as Stenotrophomonas spp. Stenotrophomonas isolates were resistant to at least six of the antibiotics tested, including Trimethoprim/Sulfamethoxazole (SXT). Conclusion: Environmental isolates from this study were resistant to SXT which is commonly used for the treatment of S. maltophilia infections. This informs the need for good public hygiene as the environment could be a reservoir of multi-resistant bacteria. It also buttresses the importance of surveillance study in the management of bacterial resistance. Keywords: Stenotrophomonas; environmental; biochemical characterization; clonal diversity; anti-microbial susceptibility.

show abstract

Detection of blaNDM-1 in Stenotrophomonas maltophilia isolated from Brazilian soil

Cited by 15 publications

References 31 publications

Co-production of blaNDM-1 and blaOXA-23 in multiresistant clinical isolates of Acinetobacter baumannii from Brazil

Co-production of blaNDM-1 and blaOXA-23 in multiresistant clinical isolates of Acinetobacter baumannii from Brazil

Treatment approaches for severe Stenotrophomonas maltophilia infections

Antimicrobial susceptibility pattern of Stenotrophomonas species isolated from Mexico

Contact Info

Product

Resources

About